Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry
Abstract Background Suhexiang (SHX) pill is widely used for treating acute ischemic stroke (AIS). Experimental and randomized controlled trials suggested that SHX pill was beneficial for patients with AIS. However, the effectiveness of SHX pill in real-world practice setting remains unclear. It is o...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Complementary Medicine and Therapies |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12906-025-04762-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571978718904320 |
|---|---|
| author | Xinxing Lai Xuejiao Xiong Qi Jia Tingting Liu Zhaowen Yang Chi Zhang Lingbo Kong Kegang Cao Ting Dong Caixia Fang Jianwen Ge Li Dong Zhitao Zong Sisi Chen Yuhong Ma Xue Bai Dahua Wu Yao Xie Mingyan Zhang Yilong Wang Guohui Jiang Daqiao Song Yanping Wang Chunyan Gui Qingwen Geng Ying Gao for the SUNRISE study investigators |
| author_facet | Xinxing Lai Xuejiao Xiong Qi Jia Tingting Liu Zhaowen Yang Chi Zhang Lingbo Kong Kegang Cao Ting Dong Caixia Fang Jianwen Ge Li Dong Zhitao Zong Sisi Chen Yuhong Ma Xue Bai Dahua Wu Yao Xie Mingyan Zhang Yilong Wang Guohui Jiang Daqiao Song Yanping Wang Chunyan Gui Qingwen Geng Ying Gao for the SUNRISE study investigators |
| author_sort | Xinxing Lai |
| collection | DOAJ |
| description | Abstract Background Suhexiang (SHX) pill is widely used for treating acute ischemic stroke (AIS). Experimental and randomized controlled trials suggested that SHX pill was beneficial for patients with AIS. However, the effectiveness of SHX pill in real-world practice setting remains unclear. It is of great importance to investigate the effectiveness and safety of SHX pill in patients with acute ischemic stroke in real-world clinical practice with long-term follow-up. Methods The Suhexiang pill for acute ischemic stroke in Real-world Practice Setting (SUNRISE) is a multicenter, prospective, product-specific, observational study designed to provide insight into the administration of SHX pill for patients with AIS in the real-world clinical practice setting, with an initial sample size of 1000. Eligible patients treated with SHX pill within seven days of AIS onset will be consecutively included in this registry. The primary outcome is the proportion of patients independent at 3 months after stroke onset defined by an mRS score of 0, 1, or 2. Conclusion The findings of the SUNRISE registry will not only provide insights into the characteristics of patients who may benefit from SHX treatment, but also may enable the individualized treatment decision-making of SHX pill in real-world practice setting. Study registration This study was registered with the ClinicalTrials.gov (URL: https://clinicaltrials.gov/ , Unique identifier: NCT05833932). |
| format | Article |
| id | doaj-art-1077fcaecf0e4ef189b0bdac8e90982e |
| institution | Kabale University |
| issn | 2662-7671 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Complementary Medicine and Therapies |
| spelling | doaj-art-1077fcaecf0e4ef189b0bdac8e90982e2025-02-02T12:08:33ZengBMCBMC Complementary Medicine and Therapies2662-76712025-01-012511710.1186/s12906-025-04762-9Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registryXinxing Lai0Xuejiao Xiong1Qi Jia2Tingting Liu3Zhaowen Yang4Chi Zhang5Lingbo Kong6Kegang Cao7Ting Dong8Caixia Fang9Jianwen Ge10Li Dong11Zhitao Zong12Sisi Chen13Yuhong Ma14Xue Bai15Dahua Wu16Yao Xie17Mingyan Zhang18Yilong Wang19Guohui Jiang20Daqiao Song21Yanping Wang22Chunyan Gui23Qingwen Geng24Ying Gao25for the SUNRISE study investigatorsDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese MedicineBeijing University of Chinese MedicineDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese MedicineDepartment of Neurology, The Affiliated Hospital of Shandong University of Traditional Chinese MedicineDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese MedicineInstitute for Brain Disorders, Beijing University of Chinese MedicineDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese MedicineDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese MedicineDepartment of Neurology, The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineDepartment of Pharmacy, Qingyang People’s HospitalDepartment of Neurology, Tianshui Hospital of Traditional Chinese MedicineDepartment of Neurology, Tianshui Hospital of Traditional Chinese MedicineDepartment of Neurosurgery, Jiujiang First People’s HospitalDepartment of Acupuncture and Moxibustion, Jiujiang Hospital of Traditional Chinese MedicineDepartment of Neurology, The Affiliated Hospital of Changzhi Institute of Traditional Chinese MedicineDepartment of Neurology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical UniversityDepartment of Neurology, Hunan Integrated Traditional Chinese and Western Medicine HospitalDepartment of Neurology, Hunan Integrated Traditional Chinese and Western Medicine HospitalDepartment of Neurology, Shehong People’s HospitalIntensive Care Unit, Shehong People’s HospitalDepartment of Neurology, The Affiliated Hospital of North Sichuan Medical CollegeDepartment of Neurology, Yiwu Hospital of Traditional Chinese MedicineDepartment of Neurology, Jiaxing Second HospitalDepartment of Neurology, Dazhou Central HospitalDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese MedicineDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese MedicineAbstract Background Suhexiang (SHX) pill is widely used for treating acute ischemic stroke (AIS). Experimental and randomized controlled trials suggested that SHX pill was beneficial for patients with AIS. However, the effectiveness of SHX pill in real-world practice setting remains unclear. It is of great importance to investigate the effectiveness and safety of SHX pill in patients with acute ischemic stroke in real-world clinical practice with long-term follow-up. Methods The Suhexiang pill for acute ischemic stroke in Real-world Practice Setting (SUNRISE) is a multicenter, prospective, product-specific, observational study designed to provide insight into the administration of SHX pill for patients with AIS in the real-world clinical practice setting, with an initial sample size of 1000. Eligible patients treated with SHX pill within seven days of AIS onset will be consecutively included in this registry. The primary outcome is the proportion of patients independent at 3 months after stroke onset defined by an mRS score of 0, 1, or 2. Conclusion The findings of the SUNRISE registry will not only provide insights into the characteristics of patients who may benefit from SHX treatment, but also may enable the individualized treatment decision-making of SHX pill in real-world practice setting. Study registration This study was registered with the ClinicalTrials.gov (URL: https://clinicaltrials.gov/ , Unique identifier: NCT05833932).https://doi.org/10.1186/s12906-025-04762-9Acute ischemic strokeSuhexiang pillTraditional Chinese medicineReal worldRegistry |
| spellingShingle | Xinxing Lai Xuejiao Xiong Qi Jia Tingting Liu Zhaowen Yang Chi Zhang Lingbo Kong Kegang Cao Ting Dong Caixia Fang Jianwen Ge Li Dong Zhitao Zong Sisi Chen Yuhong Ma Xue Bai Dahua Wu Yao Xie Mingyan Zhang Yilong Wang Guohui Jiang Daqiao Song Yanping Wang Chunyan Gui Qingwen Geng Ying Gao for the SUNRISE study investigators Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry BMC Complementary Medicine and Therapies Acute ischemic stroke Suhexiang pill Traditional Chinese medicine Real world Registry |
| title | Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry |
| title_full | Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry |
| title_fullStr | Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry |
| title_full_unstemmed | Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry |
| title_short | Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry |
| title_sort | suhexiang pill for acute ischemic stroke in real world practice setting sunrise protocol of a multicenter registry |
| topic | Acute ischemic stroke Suhexiang pill Traditional Chinese medicine Real world Registry |
| url | https://doi.org/10.1186/s12906-025-04762-9 |
| work_keys_str_mv | AT xinxinglai suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT xuejiaoxiong suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT qijia suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT tingtingliu suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT zhaowenyang suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT chizhang suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT lingbokong suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT kegangcao suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT tingdong suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT caixiafang suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT jianwenge suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT lidong suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT zhitaozong suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT sisichen suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT yuhongma suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT xuebai suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT dahuawu suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT yaoxie suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT mingyanzhang suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT yilongwang suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT guohuijiang suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT daqiaosong suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT yanpingwang suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT chunyangui suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT qingwengeng suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT yinggao suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry AT forthesunrisestudyinvestigators suhexiangpillforacuteischemicstrokeinrealworldpracticesettingsunriseprotocolofamulticenterregistry |